Pascal Grandé

Associate

Munich + 49.89.20.60.42.200

Connect:

Share

Pascal Grandé focuses on intellectual property law, particularly in the areas of national and international patent litigation.

Pascal has worked extensively on patent infringement, prosecution, invalidation proceedings, and preliminary injunctions across numerous technology sectors, including aircraft cabin electronics, photo ablative lasers, automotive, med tech, life sciences, amino acid producing bacteria, and consumer products.

In addition, he has experience in trade secret misappropriation cases and has advised on several M&A transactions regarding IP and commercial matters and on global license and distribution agreements. He also has worked extensively on compliance matters, including internal investigations and trade secret compliance.

Prior to earning his second state exam, Pascal served as a legal trainee and intern in Munich and London where he worked on product liability and patent litigation projects and on M&A transactions.

Experience

  • BioMarin pursues litigation against Ascendis Pharma A/S in UPCJones Day represents BioMarin Pharmaceutical, Inc. in patent infringement proceedings against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court (UPC) in Munich, Germany. The patent covers long-acting variants of C-Type Natriuretic Peptide ("CNP").
  • Vibrantz moves to invalidate sinter paste patent before Unified Patent Court in MunichJones Day represents Vibrantz GmbH, a manufacturer of specialty chemicals and materials, in patent invalidation counterclaim proceedings before the Unified Patent Court, Munich local division, in a dispute over certain precious metal sinter pastes for chip bonding.
  • Vibrantz defends patent dispute before Unified Patent Court in MunichJones Day represents Vibrantz GmbH, a manufacturer of specialty chemicals and materials, in patent litigation before the Unified Patent Court, Munich local division, in a dispute over certain precious metal sinter pastes for chip bonding.
  • TotalEnergies acquires Quadra EnergyJones Day advised TotalEnergies SE in the acquisition of Quadra Energy GmbH.
  • Affinity Partners leads €207 million Series F financing of EGYMJones Day represented Affinity Partners in its acquisition of an interest in EGYM, a global fitness technology and corporate health innovation leader, in a Series F financing of €107 million, with an additional €100 million available for future investments.
  • Tikehau Capital leads €13 million Series A funding of Build38 GmbHJones Day advised Tikehau Capital as lead investor in the €13 million Series A financing of Build38 GmbH, a leading provider of mobile application protection solutions that combine AI-powered threat intelligence and the strongest app shielding technology, with subsidiaries in Spain and Singapore.
  • CJ CheilJedang defends German patent infringement action by Japanese competitorJones Day represented CJ CheilJedang Corporation, a major Korean-based multinational company, in an international patent dispute with a Japanese competitor before the courts in Germany, including the Federal Supreme Court of Germany.
  • UPL sells stake in Advanta Enterprises to KKRJones Day advised UPL Limited in its $300 million sale of a 13.33% stake in its subsidiary, Advanta Enterprises Limited, to KKR.
  • Findos Investor sells Rhenoflex GmbH to Coats GroupJones Day advised Findos Investor GmbH in the €115 million sale of Rhenoflex GmbH, one of the leading global manufacturers of sustainable structural material solutions for the footwear industry, to Coats Group plc.
    • View All

    March 2023 Handout

    Information on Opting European Patents Out of the UPC System

    March 2023 Handout

    Information on Requesting a Unitary Patent

    November 2022 Commentary

    Exclusive and Non-Exclusive Licenses: Opportunities and Pitfalls Before the UPC

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.